amyotrophic lateral sclerosis

Latest Headlines

Latest Headlines

Targeting ALS, GlaxoSmithKline and Avalon seed another build-to-buy startup

Partners GlaxoSmithKline and Avalon Ventures have seeded a 7th startup in their company-building collaboration, lining up $10 million for a new effort to treat ALS.

Biogen teams up with Columbia to decode ALS

Biogen is joining Columbia University in an effort to sequence the genes of 1,500 people with amyotrophic lateral sclerosis, or ALS, hoping to better understand the disease's underlying biology to inform drug R&D.

Shifting positions, Genervon now admits it has yet to file for ALS drug OK

The Wall Street Journal has caught up with the Genervon controversy, recapping a series of events from the last few days that followed the big social media campaign to gain an instant approval for a new ALS drug based on the results of a 12-patient study. FierceBiotech readers will know already that the data were questioned by Steve Perrin, president and chief scientific officer of the ALS Therapy Development Institute, and that the FDA followed up a day later with an extraordinary challenge to Genervon to publish the data on a drug that the biotech has touted as a major advance for patients.

Scientists replicate ALS dementia in mice

Northwestern University researchers have developed the first animal model for dementia associated with amyotrophic lateral sclerosis.

Google's Calico acquires UT Southwestern compounds for neurodegenerative disorders

A new class of compounds discovered by investigators at the University of Texas Southwestern Medical Center that could treat a range of neurodegenerative disorders has caught the eye of Google's new biotechnology venture Calico.

Antioxidant could slow progression of Lou Gehrig's disease, extend lifespan

An antioxidant discovered more than a dozen years ago may be able to treat patients with amyotrophic lateral sclerosis, a devastating neurodegenerative disease that is usually fatal within 5 years of diagnosis that currently has no cure.

Glaxo compound slows Lou Gehrig's disease in animal models

A team headed by researchers at the University of Pennsylvania has figured out a way to reduce the toxicity of Lou Gehrig's disease by slowing neuron dysfunction in animal models. The discovery could offer a new way to treat the disease, also known as amyotrophic lateral sclerosis, or ALS.

Eli Lilly, Project A.L.S. forge preclinical drug discovery pact

Eli Lilly and the nonprofit Project A.L.S. are teaming up to boost the pipeline of potential drugs for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig' disease.

Industry Voices: Researching ALS through new eyes--Why data science will foster life science breakthroughs

An innovative new approach, drawing on the disciplines of both medical science and data science, offers the promise of an unprecedented breakthrough in the search for a cure for amyotrophic lateral sclerosis.

Cytokinetics patches up ALS drug trial after costly study snafu

Forced to remedy an error in a study for a potential ALS drug, Cytokinetics has revealed plans to amend the protocol of the midstage trial with expanded enrollment.